- HAS Healthcare Advanced Synthesis SA Group has announced a five-year strategic investment plan of more than CHF 100 million across its Swiss sites.
- The programme focuses on expanding CDMO services, HPAPI capabilities, and ADC conjugation capacity to support development through commercial manufacturing.
HAS Healthcare Advanced Synthesis SA Group has announced a strategic investment plan of more than CHF 100 million to strengthen its position in contract development and manufacturing and antibody–drug conjugate (ADC) production. The plan follows the integration of HAS and Cerbios and marks the close of the group’s first year operating as a combined organisation.
The five-year programme will be implemented across the group’s Biasca and Lugano sites in Switzerland. It is intended to expand capacity in core CDMO areas, broaden service and technology offerings, and accelerate development in ADC manufacturing, including high-potency active pharmaceutical ingredients (HPAPIs).
As part of the investment, the group plans to expand ADC conjugation and linker-payload capabilities. This includes a new large-scale conjugation line with capacity of up to 500 litres, expected to be operational by May 2026, and a second 500-litre commercial line scheduled for commissioning in the first quarter of 2028. Additional expansion at the Biasca site is planned to support commercial ADC production and client launches.
The company said the strategy is designed to support partners from early development through to commercial-scale production within a CDMO and contract manufacturing framework. To support the expansion, more than 30 professionals have already been hired across technical, scientific and managerial roles, with further recruitment planned in 2026.
“These investments reaffirm our commitment to being a trusted strategic partner for ADC and HPAPI development and manufacturing, delivering innovative solutions and commercial-scale capabilities.”
Riccardo Braglia, Chairman of the HAS Group
